Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Prostate cancer is characterized by aberrant lipid metabolism, including elevated fatty acid oxidation. Carnitine palmitoyltransferase 1B (CPT1B) catalyzes the rate‐limiting step of fatty acid oxidation. This study aimed to determine if CPT1B has a critical role in prostate cancer progression and to identify its regulatory mechanism.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p><i>CPT1B </i> expression data from The Cancer Genome Atlas and Gene Expression Omnibus databases was compared with patient survival data. A tissue microarray was constructed with 60 samples of prostate cancer and immunohistochemically stained for CPT1B. Castration‐resistant prostate cancer (CRPC) cell lines 22RV1 and C4‐2 in which <i>CPT1B </i> expression had been stably knocked down were established; and cell proliferation, cell cycle distribution, and invasion were investigated by Cell Counting Kit‐8 (CCK‐8) and colony formation assays, flow cytometry, and Transwell assays, respectively. To examine the impact of androgen receptor (AR) inhibition on <i>CPT1B </i> expression, JASPAR CORE was searched to identify AR‐binding sites in CPT1B. Dual luciferase and ChIP assays were performed to confirm CPT1B activity and AR binding, respectively. Differentially expressed genes (DEGs) in prostate cancer underwent gene set enrichment analysis (GSEA). Enzalutamide‐resistant C4‐2 cells were generated and the mechanism of enzalutamide resistance and downstream signaling pathway changes of CPT1B to C4‐2 was explored through CCK‐8 test. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p><i>CPT1B </i> expression was upregulated in human prostate cancer compared with normal prostate tissue and was associated with poor disease‐free survival and overall survival. Silencing of <i>CPT1B </i> resulted in downregulated cell proliferation, reduced S‐phase distribution, and lower invasive ability, whereas the opposite was observed in CRPC cells overexpressing CPTB1. DEGS in prostate cancer were correlated with G‐protein–coupled receptor signaling, molecular transducer activity, and calcium ion binding. AR may regulate <i>CPT1B </i> expression and activity via specific binding sites, as confirmed by dual luciferase and ChIP assays. The CCK‐8 experiment demonstrated that CPT1B overexpression in C4‐2 cells did not significantly increase the ability of enzalutamide resistance. However, overexpression of CPT1B in C4‐2R cells significantly increased the enzalutamide resistance. Upregulation of CPT1B expression increased AKT expression and phosphorylation. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>CPT1B is upregulated in prostate cancer and is correlated with poor prognosis, indicating its potential as a biomarker. AR inhibits the transcription of CPT1B. In the CRPC cell line, overexpression of CPT1B alone cannot promote enzalutamide resistance, but in the drug‐resistant line C4‐2R, overexpression of CPT1B can promote the resistance of C4‐2R to enzalutamide.</p></section>

BMI1 Regulates Androgen Receptor in Prostate Cancer Independently of the Polycomb Repressive Complex 1.

BMI1 is Directly Regulated by Androgen Receptor to Promote Castration-Resistance in Prostate Cancer

Bmi1 Polycomb Group Protein Acts As A Master Switch For Growth And Death Of Tumor Cells: Regulates Tcf4-Transcriptional Factor-Induced Bcl2 Signaling

CRABP2 Promotes Cell Migration and Invasion by Activating PI3K/AKT and MAPK Signalling Pathways Via Upregulating LAMB3 in Prostate Cancer

USP54 is a potential therapeutic target in castration-resistant prostate cancer

BMI1 activates P-glycoorotein via transcription repression of <i>miR</i>-<i>3682</i>-<i>3p</i> and enhances chemoresistance of bladdder cancer cell

BMI1 Regulates Multiple Myeloma-Associated Macrophage’s Pro-Myeloma Functions

MYSM1-AR complex-mediated repression of Akt/c-Raf/GSK-3β signaling impedes castration-resistant prostate cancer growth

BMI-1, a promising therapeutic target for human cancer.

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

BMI1 Fine-Tunes Gene Repression and Activation to Safeguard Undifferentiated Spermatogonia Fate.

HMGB1 Promotes the Development of Castration‑resistant Prostate Cancer by Regulating Androgen Receptor Activation

Targeting CPT1B as a potential therapeutic strategy in castration‐resistant and enzalutamide‐resistant prostate cancer

PC-1 Works in Conjunction with E3 Ligase CHIP to Regulate Androgen Receptor Stability and Activity

BMI‐1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypes

BMI1 drives metastasis of prostate cancer in Caucasian and African-American men and is a potential therapeutic target: hypothesis tested in race-specific models.

YAP1 Regulates Prostate Cancer Stem Cell-Like Characteristics to Promote Castration Resistant Growth

Protein Phosphatase 1 Suppresses Androgen Receptor Ubiquitylation and Degradation

Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer

CUL4B regulates cancer stem-like traits of prostate cancer cells by targeting BMI1 via miR200b/c.

Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo